Globe Life (GL)
NYSEFinancialsInsurance - LifeSnapshot 2026-09-04
$174.27-1.27%
Close 2026-09-04 · 1-day change
NYSEFinancialsInsurance - LifeSnapshot 2026-09-04
QuarterlyIQ Insights · GL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within financials on a research-validated quality screen. As of 2026-09-04.
The screen ranks GL against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Financials names rated neutral grew net income 55% of the time over the next year (vs 62% for the rest of the cohort, n=10246).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management has repeatedly increased full-year 2026 earnings guidance, reflecting focus on growing net operating income per share.
Stated as a priority in 4 of last 4 quarters. Management raised full-year 2026 EPS guidance from $14.60-$15.30 in 2025-Q3 to $15.55-$15.95 in 2026-Q2, reflecting a $1.15 increase at midpoint. This trajectory matches management's repeated guidance increases and shows delivering progress.
“The Company also increased full-year 2026 earnings guidance to a range of $15.55 to $15.95, an increase of $0.10 at the midpoint.”
“The Company also increased full-year 2026 earnings guidance to a range of $15.40 to $15.90, an increase of $0.35 at the midpoint.”
“Globe Life projects net operating income between $14.95 to $15.65 per diluted common share for the year ending December 31, 2026, an increase from the previous guidance.”
“For the year ending December 31, 2026, we estimate that net operating income per share will be in the range of $14.60 to $15.30.”
Management focuses on growing life and health insurance net sales across divisions, supported by agent count growth.
Stated as a priority in 6 of last 6 quarters. Life net sales showed modest growth with some quarters up to 11%, while health net sales showed stronger growth, reaching 58% in 2026-Q1 and 71% in 2025-Q4. Agent counts increased consistently. The trajectory shows delivering growth in net sales across segments.
“Health net sales increased 4% at Family Heritage and 10% at United American over the year-ago quarter.”
Management continues to repurchase shares regularly, supporting capital return to shareholders.
Stated as a priority in 6 of last 6 quarters. Share repurchases occurred each quarter, with 1.1 million shares repurchased for $175 million in 2026-Q2 and similar activity in prior quarters. This consistent repurchase activity shows delivering on capital return commitments.
“1.1 million shares repurchased during the quarter at a total cost of $175 million.”
Over the trailing year it converted 1.51x of net income into operating cash flow. Historically, Financials names rated neutral grew net income 60% of the time over the next year (vs 57% for the rest of the cohort, n=9112).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, the US dollar, long-term interest rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by executive changes. Historically, Financials names rated neutral grew net income 56% of the time over the next year (vs 58% for the rest of the cohort, n=3751).
Not investment advice. As of 2026-09-04.
“Life net sales grew 6% and health net sales increased 58% over the year-ago quarter.”
“Life net sales increased 11% and health net sales increased 71% over the year-ago quarter.”
“Life net sales increased 2% and health net sales increased 21% over the year-ago quarter.”
“Life net sales declined 1% and health net sales increased 24% over the year-ago quarter.”
“Life net sales increased 11% and health net sales increased 6% over the year-ago quarter.”
“1.4 million shares repurchased during the quarter at a total cost of $203 million.”
“1.3 million shares repurchased during the quarter at a total cost of $170 million.”
“840,242 shares repurchased during the quarter at a total cost of $113 million.”
“1.5 million shares repurchased during the quarter at a total cost of $177 million.”
“337,821 shares repurchased during the quarter at a total cost of $36 million.”